Citations

Clear

4 citation(s) found for "Meulen, Jan ter".

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Somaiah, Neeta , Chawla, Sant P. , Block, Matthew S. , Morris, John C. , Kim, Joseph W. , Druta, Mihaela , Sankhala, Kamalesh K. , Hwu, Patrick , Jones, Robin L. , Gnjatic, Sacha , Tuballes, Kevin , Yishak, Mahlet, Yakovich, Adam J., Meulen, Jan ter , Chen, Michael , Bohac, Chet, Gnjatic, Sacha , Jones, Robin L , Khanh, T. , Kim-Schulze, Seunghee , Lu, Hailing , Kenney, Richard T , Pollack, Seth M.

Mayo Clinic

OncoImmunology | November 19, 2020 | Volume: 9 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1847846 | PMID 33312760 Get It

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Somaiah, Neeta , Block, Matthew S. , Kim, Joseph W. , Shapiro, Geoffrey I. , Khanh, T. , Hwu, Patrick , Jones, Robin L. , Meulen, Jan H. ter, Bohac, Chet, Hsu, Frank J., Gnjatic, Sacha , Gnjatic, Sacha , Jones, Robin L , Shapiro, Geoffrey I , Hwu, Patrick , Eder, Joseph P. , Lu, Hailing , Chen, Michael , Pollack, Seth M.

Mayo Clinic

Clinical Cancer Research | June 21, 2019 | Volume: 25 | Issue: 19 | Pages: 5808-5817

10.1158/1078-0432.ccr-19-1025 | PMID 31227504 Get It

Abstract Purpose: LV305 is a modified, third-generation, nonreplicating, integration-deficient lentivirus-based vector designed to selectively transduce dendritic cells in vivo. LV305 induces expression of the New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) cancer testis antigen in dendritic cells, promoting immune responses against NY-ESO-1–expressing tumors. This phase I study evaluated the safety, immunogenicity, and preliminary efficacy of LV305 in patients with sarcoma or other solid tumors. Patients and Methods: Adults with previously treated, advanced, NY-ESO-1–positive solid tumors and limited tumor burden were eligible. LV305 was administered every 3 weeks by intradermal injection in four dose cohorts (Cohort 1: 108 vector genomes (vg) x 3 doses; Cohorts 1A, 2, and 3: 108 vg, 109 vg, 1010 vg x 4 doses). Results: Thirty-nine patients were enrolled: 3 patients each in Cohorts 1, 1A, and 2, and 30 patients in Cohort 3. No dose-limiting toxicities were observed. Tumor types included sarcoma (n = 24), ovarian (n = 8), melanoma (n = 6), and lung cancer (n = 1). All treatment-related adverse events were grade 1 or 2. Common treatment-related adverse events were fatigue (49%), injection site reactions (46%), and myalgia (21%). The disease control rate was 56.4% in all patients and 62.5% in sarcoma patients. One patient with synovial sarcoma achieved a partial response lasting >36 months. Anti–NY-ESO-1-specific CD4+ and/or CD8+ T cells were induced in 57% of evaluable sarcoma patients. Induction of an anti–NY-ESO-1 immune response was associated with improved 1-year survival in an exploratory analysis. Conclusions: This first-in-class, first-in-human study of LV305 demonstrated a favorable safety profile, induction of antigen-specific responses, and potential clinical activity in patients with advanced cancer.
Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.
Somaiah, Neeta , Chawla, Sant P. , Morris, John C. , Tu, Khanh, Block, Matthew S. , Yusko, Erik, Hsu, Frank J., Bohac, Gerry C., Gnjatic, Sacha , Meulen, Jan ter , Gnjatic, Sacha , Pollack, Seth M. , Lu, Hailing , Kim, Joseph W. , Vignali, Marissa , Rytlewski, Julie

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3090-3090

10.1200/jco.2017.35.15_suppl.3090 Get It

3090 Background: The correlation of immune response (IR) and clinical benefit in patients (pts) who receive active immunotherapy remains controversial. CMB305 is an active immunotherapy designed to generate and expand anti-NY-ESO-1 T cells, consisting of LV305 (a DC targeting lentiviral vector encoding NY-ESO-1) and a boost (NY-ESO-1 recombinant protein plus GLA-SE, a TLR-4 agonist). Phase 1 studies of LV305 and CMB305 evaluated the IR and survival of pts with NY-ESO-1 positive tumors. Methods: 62 pts with recurrent NY-ESO-1 expressing (by IHC) solid tumors were enrolled in 2 Phase 1 trials (31 pts each: 43 sarcomas, 12 ovarian, 4 melanomas, and 3 NSCLC). Peripheral blood was assessed pre and post therapy for anti-NY-ESO-1 T cell responses (IFNγ ELISPOT) and antibodies (Ab) (ELISA) (n = 62), TCR-β CDR3 repertoire and conserved (public) TCR (n = 28), and antigen spreading (ELISA, ELISPOT) (n = 23). Relationship between progression-free survival (PFS), overall survival (OS) and up to 15 biomarkers were analyzed by the Kaplan-Meier method. Results: Preexisting anti-NY-ESO-1 T cells and Ab were identified in 34% and 40% of pts. LV305 and CMB305 induced (de novo or increased) anti-NY-ESO-1 T-cells in 51% and 65% pts, and anti-NY-ESO-1 Ab responses in 13% and 68% pts, respectively. LV305 and CMB305 induced antigen spreading in 17% and 36% pts. TCR clonality increased after CMB305 as compared to LV305. The TCRβ-CDR3 amino acid sequences of three NY-ESO-1 specific TCR clones in a patient with a > 2-year response were fully conserved in 20/28 patients. Biomarkers showing the strongest association with OS and PFS were pre-existing anti-NY-ESO-1 T-cell response and Ab, integrated IR (T cells and antibodies), and NY-ESO-1 expression level. Presence of public TCRs was associated with longer survival, particularly in pts with high ( > 50%) NY-ESO-1 expression. Conclusions: While LV305 and CMB305 are both immunogenic, CMB305 resulted in a stronger and broader integrated IR, including antigen spreading. The three identified survival variables, preexisting and treatment-induced NY-ESO-1 IR and the presence of public TCRs, warrant validation in randomized studies of CMB305.
Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.
Somaiah, Neeta , Block, Matthew S. , Tu, Khanh, Hwu, Patrick , Jones, Robin L. , Gnjatic, Sacha , Lu, Hailing , Meulen, Jan ter , Hsu, Frank J., Gnjatic, Sacha , Jones, Robin L , Kim, Joseph W. , Shapiro, Geoffrey I. , Eder, Joseph P. , Pollack, Seth M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3093-3093

10.1200/jco.2016.34.15_suppl.3093 Get It